In Vivo Circrna-Engineered Macrophages Mediate Localized Mmp9 Neutralization To Rejuvenate Aged Bone
Our bodies change as we age, and our bones are no exception. Many older adults face challenges like weakened bones (osteoporosis) and slow healing after fractures, largely due to a lack of effective treatments. Recent research has pinpointed a specific protein, called MMP9, as a major culprit in these age-related bone problems. When there’s too much MMP9, it contributes to the decline in bone health.
Scientists have now developed an innovative way to tackle this issue. They’ve engineered a type of immune cell, called a macrophage, to act as a tiny delivery system. These engineered cells carry special genetic instructions, packaged within tiny fat-like particles, that enable them to produce antibodies specifically designed to block MMP9. By delivering these anti-MMP9 antibodies directly to where they’re needed, this method aims to reverse the effects of aging on our bones.
In studies with aged mice, this novel approach showed remarkable results. It significantly reduced the aging of stem cells and boosted the formation of new bone. Furthermore, it sped up the healing of fractures and even helped reduce the breakdown of cartilage. The mechanism behind this success involves the blockade of MMP9, which helps to calm down age-related inflammatory signals and restore the natural balance between bone-building and bone-resorbing cells. This groundbreaking work not only highlights MMP9’s crucial role in skeletal aging but also introduces a promising new form of therapy that could revolutionize how we treat age-related bone conditions.
Source: link to paper